Polares Medical SA

Polares Medical S. A. is dedicated to developing innovative medical devices that address mitral valve regurgitation, enhancing patient care with minimally invasive solutions. Founded in 2010 and headquartered in Palo Alto, US, Polares Medical S.

A. specializes in creating medical devices for mitral valve regurgitation. In March 2026, Polares Medical S. A.

raised USD 50 million in series C funding from DC Global Ventures and Lumination Partners, with participation from other unspecified investors. Polares Medical specializes in innovative medical devices aimed at addressing mitral valve regurgitation, characterized by improper closure of the heart’s mitral valve. Their flagship product is a novel mitral valve treatment device designed to restore valve function with minimal invasiveness, improving recovery times and overall patient experiences. Their primary clientele includes hospitals, cardiology clinics, and healthcare professionals focused on cardiac care, targeting patients with symptomatic mitral valve regurgitation.

The company markets its products across North America, Europe, and select Asian markets, increasing access to advanced cardiac treatments. Polares Medical generates revenue through direct sales of its medical devices to healthcare institutions, including hospitals and specialized cardiac care facilities. These transactions are structured as business-to-business exchanges, ensuring access to necessary equipment for patient treatment, with pricing plans consistent with industry standards for medical devices. The company is focused on forging strategic partnerships with healthcare providers to facilitate the adoption of its innovative solutions as it expands its market presence.

Polares Medical plans to utilize the USD 40 mn raised in June 2020 to support the development and launch of new products aimed at further enhancing treatment options for mitral valve regurgitation. The company is also targeting expansion into additional geographic regions, specifically increasing its footprint in Europe and Asia by 2023. The company plan to use the March 2026 funding to progress clinical trials across the US, Europe, and Australia. The company is led by CEO Jacques Essinger.